Minerva Neurosciences Valuation Multiples
Minerva Neurosciences is valued at $116M as of November 2026. In the last fiscal year, Minerva Neurosciences EBITDA was ($293M).
Minerva Neurosciences Overview
About Minerva Neurosciences
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
Founded
2007
HQ
Employees
8
Website
Financials (Last FY)
EV
$50M
Valuation Multiples
Start free trial
Minerva Neurosciences Financials
Minerva Neurosciences reported last fiscal year revenue of - and negative EBITDA of ($293M).
In the same fiscal year, Minerva Neurosciences generated ($293M) in EBITDA losses and had net loss of ($293M).
Revenue (LTM)
Minerva Neurosciences P&L
In the most recent fiscal year, Minerva Neurosciences reported revenue of - and EBITDA of ($293M).
Minerva Neurosciences is unprofitable as of last fiscal year, with EBITDA margin of - and net margin of -.
Financial data powered by Morningstar, Inc.
Minerva Neurosciences Stock Performance
Minerva Neurosciences has current market cap of $116M, and enterprise value of $50M.
Market Cap Evolution
Minerva Neurosciences' stock price is $2.42.
Minerva Neurosciences share price increased by 4.3% in the last 30 days.
Minerva Neurosciences has an EPS (earnings per share) of $-6.15.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $50M | $116M | 0.0% | 4.3% | - | - | $-6.15 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialMinerva Neurosciences Valuation Multiples
Minerva Neurosciences trades at (0.2x) EV/EBITDA.
Minerva Neurosciences Financial Valuation Multiples
As of November 8, 2026, Minerva Neurosciences has market cap of $116M and EV of $50M.
Minerva Neurosciences has a P/E ratio of (0.8x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Minerva Neurosciences Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Minerva Neurosciences Margins & Growth Rates
Minerva Neurosciences decreased net profit by 56% in the last fiscal year.
Minerva Neurosciences Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Minerva Neurosciences Operational KPIs
Minerva Neurosciences' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $1.9M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
Minerva Neurosciences Competitors
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
This data is available for Pro users. Sign up to see all Minerva Neurosciences competitors and their valuation data. Start Free Trial | ||||||
Minerva Neurosciences VC Funding History
Before going public, Minerva Neurosciences raised $80M in total equity funding, across 1 round.
Minerva Neurosciences Funding Rounds
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Minerva Neurosciences
| When was Minerva Neurosciences founded? | Minerva Neurosciences was founded in 2007. |
| Where is Minerva Neurosciences headquartered? | Minerva Neurosciences is headquartered in United States. |
| How many employees does Minerva Neurosciences have? | As of today, Minerva Neurosciences has over 8 employees. |
| Is Minerva Neurosciences publicly listed? | Yes, Minerva Neurosciences is a public company listed on Nasdaq. |
| What is the stock symbol of Minerva Neurosciences? | Minerva Neurosciences trades under NERV ticker. |
| When did Minerva Neurosciences go public? | Minerva Neurosciences went public in 2014. |
| Who are competitors of Minerva Neurosciences? | Minerva Neurosciences main competitors include |
| What is the current market cap of Minerva Neurosciences? | Minerva Neurosciences' current market cap is $116M. |
| Is Minerva Neurosciences profitable? | No, Minerva Neurosciences is not profitable. |
| What is the current net income of Minerva Neurosciences? | Minerva Neurosciences' last 12 months net income is ($153M). |
| How many companies Minerva Neurosciences has acquired to date? | Minerva Neurosciences hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Minerva Neurosciences has invested to date? | Minerva Neurosciences hasn't invested in any companies yet (or none have been disclosed publicly). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.